{
    "clinical_study": {
        "@rank": "127595", 
        "acronym": "PCSAM", 
        "arm_group": [
            {
                "arm_group_label": "Conventional treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Lipidlowering: \"Atorvastatin\" (Liprimar) - 40mg per day. Antihypertensive: \"Diroton\" (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and \"Ditiazem\" (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.\nAntihyperglycemic drugs: biguanides \"Metformin\" - 0.5 g two or tree times per day, or \"Exenatide\" - 5-10 \u00b5g per day.\nAnti-inflammatory: \"TromboACC\" (acetylsalicylate acid) up to 2 g per day and/or \"Clopidogrel\" (thienopyridine class antiplatelet agent) - 75mg per day."
            }, 
            {
                "arm_group_label": "Weight loss treatment", 
                "arm_group_type": "Experimental", 
                "description": "Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity."
            }
        ], 
        "brief_summary": {
            "textblock": "Study the mechanisms of atherosclerosis based on a comparative study of physical and\n      chemical properties of lipid tissues at various localization with subsequent development of\n      concept of treatment and prevention."
        }, 
        "brief_title": "Physical and Chemical Study of Atherosclerosis Mechanisms", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Myocardial Infarction", 
            "Coronary Artery Diseases", 
            "Diabetes Mellitus, Type 2", 
            "Atherosclerosis of Femoral Artery"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "The chemical and physical properties of different lipids of body. The clinical part of the\n      work is a prospective randomized comparative controlled clinical trial of patients with\n      atherosclerotic diseases.\n\n      Developed the concept of \"limited biological resources\" of the body based on the increase in\n      the expenditure of energy reserves of the body, allowing a critical look at overweight.\n\n      The role of overweight in the development of atheromatous fat was revealed. The positive\n      results from the weight loss in patients with atherosclerotic disease were drawn. Developed\n      the metabolic concept of atherosclerosis associated with evolutionary aging and conversion\n      of lipids in hard atherosclerotic fat."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  written informed consent form\n\n          -  dyslipidemia (HDL <1.0 mmol / l, triglycerides (TG) in plasma \u2265 1,7 mmol / l or\n             cholesterol \u2265 5,6 mmol /l)\n\n          -  waist circumference \u2265 94.0 cm in men or \u2265 80,0 cm in women,\n\n          -  BP \u2265140/95 mm Hg or a patient is taking antihypertensive medications,\n\n          -  fasting glucose \u2265 6,1 mmol / l or the patient is taking hypoglycemic agents,\n\n          -  the possibility of treatment for 6 months and follow-up for 1 year\n\n        Exclusion Criteria:\n\n          -  Absence of consent form\n\n          -  Non-compliance of patient to necessary recommendations.\n\n          -  The presence of mental illness.\n\n          -  Complete immobilization of a patient (paresis, and paralysis)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "26 Years"
        }, 
        "enrollment": {
            "#text": "97", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700075", 
            "org_study_id": "0109RK000079"
        }, 
        "intervention": [
            {
                "arm_group_label": "Conventional treatment", 
                "description": "Lipidlowering: \"Atorvastatin\" (Liprimar) - 40mg per day. Antihypertensive: \"Diroton\" (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and \"Ditiazem\" (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.\nAntihyperglycemic drugs: biguanides \"Metformin\" - 0.5 g two or tree times per day, or \"Exenatide\" - 5-10 \u00b5g per day.\nAnti-inflammatory: \"TromboACC\" (acetylsalicylate acid) up to 2 g per day and/or \"Clopidogrel\" (thienopyridine class antiplatelet agent) - 75mg per day.", 
                "intervention_name": "Conventional treatment", 
                "intervention_type": "Drug", 
                "other_name": "Pathogenetic and symptomatic treatment"
            }, 
            {
                "arm_group_label": "Weight loss treatment", 
                "description": "Weight loss treatment by administering a healthy very low-calorie, low-fat  vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.", 
                "intervention_name": "Weight loss treatment", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "vegetable and salt diet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antihypertensive Agents", 
                "Hypoglycemic Agents", 
                "Platelet Aggregation Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "atherosclerosis, development of concept, weight loss therapy", 
        "lastchanged_date": "October 3, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Almaty", 
                    "country": "Kazakhstan", 
                    "zip": "050000"
                }, 
                "name": "Scientific Research Institute of Cardiology and Internal Diseases"
            }
        }, 
        "location_countries": {
            "country": "Kazakhstan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Physical and Chemical Study of the Mechanisms of Atherosclerosis With Development of Concept of Treatment and Prevention", 
        "overall_official": {
            "affiliation": "Scientisic research institute of cardiology and internal diseases", 
            "last_name": "Kuat P Oshakbayev, MD, PhD, DsC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Kazakhstan: Ethical Commission", 
                "Kazakhstan: Ministry of Public Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Regression of atherosclerosis plaque in vessel: imaging methods (GE Vivid 7 Ultrasound; GE Healthcare Worldwide USA, Michigan), and computed tomography scans (AG Siemens Somatom Emotion 6, Germany, Muenchen).\nImprovement of clinical condition: by measurement of clinical presence status.", 
            "measure": "full recovery from atherosclerotic diseases", 
            "safety_issue": "Yes", 
            "time_frame": "for 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700075"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Weight loss: Tanita-SC330S Body Composition Analyzer (Tanita Corp., Tokyo, Japan) including weight (kg), body mass index (BMI, kg/m2), body composition parameters, including as fat mass (in % of total body weight and total kg), visceral fat rating (units), fat free mass (kg), total body water (in % and kg), muscle mass (in % and kg), bone mass (in % and kg), metabolic age (years), basal metabolic rate (kcal per day), and bioimpedance (Ohms).\nRate of blood circulation: Dopler Ultrasound (GE Healthcare Worldwide USA, Michigan).\nBone density: bone densitometry (Lunar Achilles Express Ultrasound; GE Healthcare USA, Madison).\nImaging of internal organs and blood vessel diameter: computed tomography scans (AG Siemens Somatom Emotion 6, Germany, Muenchen).\nGeneral clinical study of blood and urine, liver and kidneys function tests, glucose and lipids levels.\nClinical condition in dynamics: clinical presence status.", 
            "measure": "normalised laboratory and instrumental data", 
            "safety_issue": "Yes", 
            "time_frame": "for 12 month"
        }, 
        "source": "Republican Scientific Center for Emergency Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, Kazakhstan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Republican Scientific Center for Emergency Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}